https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.00293/full
Frontiers | A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa
The global increase in multidrug-resistant (MDR) bacteria has led to phage therapy being refocused upon. A novel endolysin, LysPA26, containing a lysozyme-li...
a novelfrontiersantimicrobialpseudomonas